Early diagnosis method and diagnostic kit for liver cancer

Abstract

The invention provides an early diagnosis method of liver cancer for a subject, comprising the steps of: 1) obtaining a biological sample from the subject; 2) detecting the content of a plurality of biomarkers in the biological sample, wherein the plurality of biomarkers are selected from two or more of AFP, AFP-L3, GP73, Fuc-GP73, DCP, CEA, CA19-9, TK1, DKK1, [Gamma]-GT, ALP, AFU, ALT and Fuc-Kininogen 1; 3) calculating the probability that the subject has liver cancer based on the detection result of step 2); and 4) comparing the probability with a set threshold, and when the probability isgreater than or equal to the set threshold, the subject is considered to have liver cancer; when the probability is less than the set threshold, the subject is considered not to have liver cancer. Theinvention also provides a corresponding detection kit and a detection device. The early diagnosis method and the diagnostic kit of liver cancer improve the sensitivity and the specificity of early diagnosis of liver cancer by the combined detection of various markers, and provide a more reliable basis for clinical diagnosis of liver cancer.

Description

technical field [0001] The invention relates to a method for early diagnosis of liver cancer, especially a method for diagnosing liver cancer combined with multiprotein markers. The invention also relates to a kit and equipment for early diagnosis of liver cancer. Background technique [0002] Hepatocellular carcinoma (HCC) is one of the common clinical malignant tumors, and its main etiology is chronic liver virus infection of HCV or HBV. At present, there are about 20 million symptomatic chronic hepatitis B patients in China, and nearly 25% to 30% of chronic hepatitis B patients can develop into liver cirrhosis. Due to the large number of liver disease patients and high-risk groups of liver cancer, the incidence of liver cancer in China ranks first in the world. According to the 2015 WHO report, there were 782,000 new cases of liver cancer and 745,000 deaths worldwide. Among them, the number of new cases and deaths in China accounted for about 50%. [0003] Clinical tr...

AI Technical Summary

Problems solved by technology

[0005] At present, the most commonly used tumor marker for the early diagnosis of liver cancer is alpha-fetoprotein (AFP), which is widely used because of its relative specificity to HCC. However, AFP is positive in some benign liver diseases (specificity ≤ 75%) and AFP is negative in some liver cancers (sensitivity ≤ 70%), which makes it limited to rely solely on AFP for HCC early warning and monitoring, and the sensitivity of AFP detection for HCV-related HCC is not high

[0006] In addition to AFP, markers that can be used for the diagnosis of liver cancer include AFP heterogeneity (AFP-L3), Golgi transmembrane protein (GP73), Golgi protein heterogeneity (Fuc-GP73), serum abnormal prothrombin (DCP) , carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA19-9), thymidine kinase 1 (TK1), secreted protein (Dikkopf-1, DKK1), γ-glutamyl transpeptidase (γ-GT ), alkaline phosphatase (ALP), α-L-fucosidase (α-L-Fucosidase, AFU), alanine aminotransferase (ALT), kininogen 1 variant (Fuc-Kininogen 1), etc., However, the sensitivity and specificity of individual indicators for the diagnosis of liver cancer are low.

Images